Veracyte, Inc. (VCYT) Stock Forecast
VCYT analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 4.38 / 5 from 13 analysts
- Price target
- $58.42 average of analyst targets
- Upside to target
- +35.5% from the latest close
- Next earnings
- November 4, 2026 EPS estimate $0.28
- 52-week range
- $30.01 – $60.49
VCYT analyst ratings
13 analystsNumber of analysts at each rating.
VCYT price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
VCYT earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.41 | $0.35 | $0.45 | $0.51 | −19.5% | 12 |
| Current fiscal year (2026) | $1.91 | $1.78 | $1.99 | $1.78 | +7.4% | 12 |
| Next fiscal year (2027) | $1.95 | $1.67 | $2.11 | $1.91 | +1.7% | 12 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
VCYT revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $147.2M | $144.9M | $148.6M | +11.6% | 12 |
| Current fiscal year (2026) | $593.7M | $589.0M | $597.9M | +14.8% | 13 |
| Next fiscal year (2027) | $658.7M | $641.7M | $681.0M | +10.9% | 13 |
VCYT EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
VCYT revenue: reported and forecast
VCYT EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.44 | $0.41 | $0.41 | $0.41 | $0.41 | −6.0% | 0 up · 1 down |
| Current fiscal year (2026) | $1.80 | $1.91 | $1.91 | $1.91 | $1.91 | +6.0% | 1 up · 1 down |
| Next fiscal year (2027) | $1.89 | $1.95 | $1.95 | $1.95 | $1.95 | +3.1% | 1 up · 2 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
VCYT earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; VCYT beat in 10 of 12.
What analysts expect from VCYT
13 analysts cover Veracyte; their consensus rating is buy (4.38 on a 1–5 scale, where 5 is a strong buy). The average price target is $58.42, 35.5% above the latest close of $43.12. Analysts expect earnings of $1.91 per share for 2026, +7.4% from a year earlier. For 2027 the average estimate is $1.95 per share on revenue of $658.7 million. Veracyte beat the EPS estimate in 10 of the last 12 quarters.
Related: VCYT income statement, VCYT key metrics, VCYT chart. See the VCYT stock overview for the latest quote and news.
VCYT forecast FAQ
What is Veracyte's price target?
The average analyst price target for Veracyte is $58.42, 35.5% above the latest close of $43.12.
Is Veracyte a buy, hold or sell?
Of 13 analysts covering Veracyte, 9 rate it a strong buy, 2 a buy, 1 a hold, 0 a sell and 1 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Veracyte's EPS forecast?
Analysts forecast $1.91 per share for 2026 (range $1.78 to $1.99); for 2027 the estimate is $1.95.
What is Veracyte's revenue forecast?
The average revenue estimate for 2026 is $593.7 million, growth of 14.8%; for 2027 it is $658.7 million.
When does Veracyte report earnings?
Veracyte is expected to report results for the quarter ending September 30, 2026 on November 4, 2026 after the market closes; the EPS estimate is $0.28.
Does Veracyte usually beat earnings estimates?
Veracyte reported EPS at or above the analyst estimate in 10 of the last 12 quarters.